Sargent Investment Group LLC Sells 13,280 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sargent Investment Group LLC lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.8% during the third quarter, HoldingsChannel.com reports. The firm owned 109,300 shares of the company’s stock after selling 13,280 shares during the period. Sargent Investment Group LLC’s holdings in Teva Pharmaceutical Industries were worth $1,970,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $52,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 1.2 %

Shares of TEVA traded down $0.20 during trading hours on Thursday, hitting $16.74. The company had a trading volume of 1,705,396 shares, compared to its average volume of 9,220,767. The company’s fifty day moving average price is $17.84 and its two-hundred day moving average price is $17.20. Teva Pharmaceutical Industries Limited has a one year low of $8.64 and a one year high of $19.31. The company has a market capitalization of $18.96 billion, a PE ratio of -19.76, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.